Silihan lan utang jangka dawa perusahaan Harrow Health (HROW)

This chart illustrates the market value of Harrow, Inc. (HROW), which is accompanied by the 0.28 indicator. The business relies on a network of ophthalmology centers, offering treatments for corneal dryness. Growth is driven by strong sales of Vevye and Iheezo, as well as the integration of Novartis assets, which has improved profitability. Current success is based on the sale of premium drops and the expansion of clinic coverage.

When screening business quality, investors assess capital stability by analyzing liabilities with maturities exceeding one year. This indicator measures the total volume of long-term loans, which, given the inelastic demand for Harrow, Inc. (HROW) ophthalmic drugs, allows for a comparison of stable cash flow against debt service costs to evaluate the deleveraging risk of the business's long-term debt.